Given the difference in mortality rates between groups (COVID-19 25%, patients infected with ACE2-associated viruses 30%, patients infected with non-ACE2-associated viruses 63%), it is possible that more patients in the non-ACE2 associated groups died before developing AKI, thereby underestimating true AKI rates among these patients. Here, ACE2 is linked to COVID-19.